keyword
MENU ▼
Read by QxMD icon Read
search

cost effectiveness of pre exposure prophylaxis

keyword
https://www.readbyqxmd.com/read/28222118/social-structural-behavioral-and-clinical-factors-influencing-retention-in-pre-exposure-prophylaxis-prep-care-in-mississippi
#1
Trisha Arnold, Lauren Brinkley-Rubinstein, Philip A Chan, Amaya Perez-Brumer, Estefany S Bologna, Laura Beauchamps, Kendra Johnson, Leandro Mena, Amy Nunn
Pre-exposure prophylaxis (PrEP) is a biomedical intervention that can reduce rates of HIV transmission when taken once daily by HIV-negative individuals. Little is understood about PrEP uptake and retention in care among the populations most heavily impacted by the HIV epidemic, particularly among young men who have sex with men (YMSM) in the Deep South. Therefore, this study explored the structural, social, behavioral, and clinical factors that affect PrEP use and retention in care among YMSM in Jackson, Mississippi...
2017: PloS One
https://www.readbyqxmd.com/read/28209492/reproductive-considerations-in-the-setting-of-chronic-viral-illness
#2
REVIEW
Brent M Hanson, Jessie A Dorais
Special considerations must be taken when patients with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C desire to achieve pregnancy. Patients with chronic viral illnesses desire children at rates similar to the general population, and options are available to decrease both vertical transmission and viral transmission between partners. Preconception counseling or consultation with fertility specialists is imperative in patients with HIV, Hepatitis B, and Hepatitis C so that reproductive goals can be addressed and optimized...
February 13, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28031062/maximizing-the-benefits-of-art-and-prep-in-resource-limited-settings
#3
G Akudibillah, A Pandey, J Medlock
Antiretroviral therapy (ART) is increasingly being used as an HIV-prevention tool, administered to uninfected people with ongoing HIV exposure as pre-exposure prophylaxis (PrEP) and to infected people to reduce their infectiousness. We used a modelling approach to determine the optimal population-level combination of ART and PrEP allocations required in South Africa to maximize programme effectiveness for four outcome measures: new infections, infection-years, death and cost. We considered two different strategies for allocating treatment, one that selectively allocates drugs to sex workers and one that does not...
December 29, 2016: Epidemiology and Infection
https://www.readbyqxmd.com/read/27989271/beyond-the-90-90-90-refocusing-hiv-prevention-as-part-of-the-global-hiv-response
#4
Rachel Baggaley, Shona Dalal, Cheryl Johnson, Virginia Macdonald, Ioannis Mameletzis, Michelle Rodolph, Carmen Figueroa, Julia Samuelson, Annette Verster, Meg Doherty, Gottfried Hirnschall
INTRODUCTION: The remarkable expansion in availability of antiretroviral therapy (ART) over the past two decades has transformed HIV infection into a manageable chronic condition. People with HIV infection now live long and healthy lives on treatment that is simpler, safer and cheaper. According to UNAIDS estimates, the global coverage of ART reached 46% in 2015, resulting in a 26% decrease in annual HIV-related deaths since 2010. Such success has positioned treatment access at the centre of the global HIV response as a way to prevent mortality, morbidity and HIV transmission through a "Treat All" approach...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27970805/systematic-review-of-studies-estimating-the-cost-effectiveness-of-hiv-pre-exposure-prophylaxis-prep-in-men-who-have-sex-with-men-msm
#5
O Damm, S Scholz, W Greiner
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27900502/values-and-preferences-on-the-use-of-oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-among-multiple-populations-a-systematic-review-of-the-literature
#6
Florence M Koechlin, Virginia A Fonner, Sarah L Dalglish, Kevin R O'Reilly, Rachel Baggaley, Robert M Grant, Michelle Rodolph, Ioannis Hodges-Mameletzis, Caitlin E Kennedy
Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection. WHO released new guidelines in 2015 recommending PrEP for all populations at substantial risk of HIV infection. To prepare these guidelines, we conducted a systematic review of values and preferences among populations that might benefit from PrEP, women, heterosexual men, young women and adolescent girls, female sex workers, serodiscordant couples, transgender people and people who inject drugs, and among healthcare providers who may prescribe PrEP...
November 29, 2016: AIDS and Behavior
https://www.readbyqxmd.com/read/27885972/protecting-the-confidentiality-and-security-of-personal-health-information-in-low-and-middle-income-countries-in-the-era-of-sdgs-and-big-data
#7
Eduard J Beck, Wayne Gill, Paul R De Lay
BACKGROUND: As increasing amounts of personal information are being collected through a plethora of electronic modalities by statutory and non-statutory organizations, ensuring the confidentiality and security of such information has become a major issue globally. While the use of many of these media can be beneficial to individuals or populations, they can also be open to abuse by individuals or statutory and non-statutory organizations. Recent examples include collection of personal information by national security systems and the development of national programs like the Chinese Social Credit System...
2016: Global Health Action
https://www.readbyqxmd.com/read/27781100/how-can-we-achieve-universal-access-to-low-cost-treatment-for-hiv
#8
EDITORIAL
Andrew M Hill, Anton L Pozniak
Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV). New combinations of ARVs costing as little as $60 per person-year will be available in the near future. Pre-exposure prophylaxis using TDF in combination with either 3TC or emtricitabine (FTC) could also be provided for less than $90 per person-year...
October 5, 2016: Journal of Virus Eradication
https://www.readbyqxmd.com/read/27760688/prep-implementation-in-the-asia-pacific-region-opportunities-implementation-and-barriers
#9
Iryna Zablotska, Andrew E Grulich, Nittaya Phanuphak, Tarandeep Anand, Surang Janyam, Midnight Poonkasetwattana, Rachel Baggaley, Frits van Griensven, Ying-Ru Lo
INTRODUCTION: HIV epidemics in the Asia-Pacific region are concentrated among men who have sex with men (MSM) and other key populations. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention and could be a potential game changer in the region. We discuss the progress towards PrEP implementation in the Asia-Pacific region, including opportunities and barriers. DISCUSSION: Awareness about PrEP in the Asia-Pacific is still low and so are its levels of use...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760687/towards-a-fair-consideration-of-prep-as-part-of-combination-hiv-prevention-in-latin-america
#10
Giovanni Ravasi, Beatriz Grinsztejn, Ricardo Baruch, Juan Vicente Guanira, Ricardo Luque, Carlos F Cáceres, Massimo Ghidinelli
INTRODUCTION: Despite progress in scaling up antiretroviral treatment, HIV prevention strategies have not been successful in significantly curbing HIV incidence in Latin America. HIV prevention interventions need to be expanded to target the most affected key populations with a combination approach, including new high impact technologies. Oral pre-exposure prophylaxis (PrEP) is recommended as additional prevention choice for individuals at higher risk of infection and could become a cost-effective prevention tool...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760685/implementation-of-pre-exposure-prophylaxis-for-human-immunodeficiency-virus-infection-progress-and-emerging-issues-in-research-and-policy
#11
Carlos F Cáceres, Annick Borquez, Jeffrey D Klausner, Rachel Baggaley, Chris Beyrer
BACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. DISCUSSION: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760682/prep-as-a-feature-in-the-optimal-landscape-of-combination-hiv-prevention-in-sub-saharan-africa
#12
Jessica B McGillen, Sarah-Jane Anderson, Timothy B Hallett
INTRODUCTION: The new WHO guidelines recommend offering pre-exposure prophylaxis (PrEP) to people who are at substantial risk of HIV infection. However, where PrEP should be prioritised, and for which population groups, remains an open question. The HIV landscape in sub-Saharan Africa features limited prevention resources, multiple options for achieving cost saving, and epidemic heterogeneity. This paper examines what role PrEP should play in optimal prevention in this complex and dynamic landscape...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760681/prep-in-europe-expectations-opportunities-and-barriers
#13
Sheena Mary McCormack, Veronica Noseda, Jean-Michel Molina
INTRODUCTION: In contrast to the global trend showing a decline in new HIV infections, the number reported in the World Health Organization (WHO) region of Europe is increasing. Health systems are disparate, but even countries with free access to screening and treatment observe continuing high rates of new infections in key populations, notably men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) is only available in France. This commentary describes the European epidemics and healthcare settings where PrEP could be delivered, how need might be estimated for MSM and the residual barriers to access...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27749602/implementation-and-operational-research-affordable-care-act-implementation-in-a-california-health-care-system-leads-to-growth-in-hiv-positive-patient-enrollment-and-changes-in-patient-characteristics
#14
Derek D Satre, Andrea Altschuler, Sujaya Parthasarathy, Michael J Silverberg, Paul Volberding, Cynthia I Campbell
OBJECTIVES: This study examined implementation of the Affordable Care Act (ACA) in relation to HIV-positive patient enrollment in an integrated health care system; as well as changes in new enrollee characteristics, benefit structure, and health care utilization after key ACA provisions went into effect in 2014. METHODS: This mixed-methods study was set in Kaiser Permanente Northern California (KPNC). Qualitative interviews with 29 KPNC leaders explored planning for ACA implementation...
December 15, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27684827/motives-of-dutch-men-who-have-sex-with-men-for-daily-and-intermittent-hiv-pre-exposure-prophylaxis-usage-and-preferences-for-implementation-a-qualitative-study
#15
Janneke P Bil, Wendy M van der Veldt, Maria Prins, Ineke G Stolte, Udi Davidovich
Although PrEP is not yet registered in Europe, including the Netherlands, its approval and implementation are expected in the near future. To inform future pre-exposure prophylaxis (PrEP) implementation, this study aimed to gain insight into motives and preferences for daily or intermittent PrEP use among Dutch HIV-negative men having sex with men (MSM).Between February and December 2013, semistructured interviews were conducted until data saturation was reached (N = 20). Interviews were analyzed using the Grounded Theory approach...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27678533/treatment-and-prevention-for-female-sex-workers-in-south-africa-protocol-for-the-taps-demonstration-project
#16
Gabriela B Gomez, Robyn Eakle, Judie Mbogua, Godspower Akpomiemie, W D Francois Venter, Helen Rees
INTRODUCTION: Updated guidelines from the WHO recommend antiretroviral treatment for adults with HIV at any CD4 count and daily oral pre-exposure prophylaxis (PrEP) for people at substantial risk of HIV infection. However, implementation challenges may hinder the ability of programmes to translate these recommendations into successful practice. This demonstration project is the first to integrate PrEP and immediate treatment (ITx) for female sex workers (FSWs) in South Africa to answer operational research questions...
2016: BMJ Open
https://www.readbyqxmd.com/read/27677264/pre-exposure-prophylaxis-for-hiv-prevention-why-what-who-and-how
#17
REVIEW
Olubanke Davies, Andrew Ustianowski, Julie Fox
Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervention, populations that may benefit, current guidelines and programmes, and the cost-effectiveness modelling of this strategy.
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27665989/cost-effectiveness-analysis-of-pre-exposure-prophylaxis-for-hiv-1-prevention-in-the-netherlands-a-mathematical-modelling-study
#18
Brooke E Nichols, Charles A B Boucher, Marc van der Valk, Bart J A Rijnders, David A M C van de Vijver
BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine prevents HIV infections among men who have sex with men (MSM). PrEP can be given on a daily or intermittent basis. Unfortunately, PrEP is not reimbursed in most European countries. Cost-effectiveness analyses of PrEP among MSM in Europe are absent but are key for decision makers to decide upon PrEP implementation. METHODS: We developed a deterministic mathematical model, calibrated to the well defined Dutch HIV epidemic among MSM, to predict the effect and cost-effectiveness of PrEP...
December 2016: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/27665722/optimizing-hiv-pre-exposure-prophylaxis-implementation-among-men-who-have-sex-with-men-in-a-large-urban-centre-a-dynamic-modelling-study
#19
Derek R MacFadden, Darrell H Tan, Sharmistha Mishra
INTRODUCTION: Once-daily tenofovir/emtricitabine-based pre-exposure prophylaxis (PrEP) can reduce HIV acquisition in men who have sex with men (MSM), by 44% in the iPrEx trial, and reaching up to 99% with high adherence. We examined the potential population-level impact and cost-effectiveness of different PrEP implementation strategies. METHODS: We developed a dynamic, stochastic compartmental model of HIV transmission among the estimated 57,400 MSM in Toronto, Canada...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27558571/a-cost-effectiveness-analysis-of-preexposure-prophylaxis-for-the-prevention-of-hiv-among-los-angeles-county-men-who-have-sex-with-men
#20
Emmanuel F Drabo, Joel W Hay, Raffaele Vardavas, Zachary R Wagner, Neeraj Sood
BACKGROUND:  Substantial gaps remain in understanding the trade-offs between the costs and benefits of choosing alternative human immunodeficiency virus (HIV) prevention strategies, including test-and-treat (expanded HIV testing combined with immediate treatment) and PrEP (initiation of preexposure prophylaxis by high-risk uninfected individuals) strategies. METHODS:  We develop a mathematical epidemiological model to simulate HIV incidence among men residing in Los Angeles County, California, aged 15-65 years, who have sex with men...
August 23, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
114595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"